China’s HQ Pharma (Shanghai) Co., Ltd has entered into a new collaboration agreement with Shanghai Pharmaceutical Import & Export Co., Ltd., a wholly owned subsidiary of Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607). This partnership builds on their existing agreement from December 2023, aiming to enhance the international market access and commercialization of HQ Pharma’s complex preparation products.
Partnership Details
The collaboration will leverage SPH’s international channel advantages to expand the global reach of HQ Pharma’s products. The two companies will work together to strengthen market access and commercialization efforts abroad, capitalizing on SPH’s extensive global network.
Strategic Synergies
By combining their strengths, HQ Pharma and SPH aim to accelerate the international commercialization of complex pharmaceutical products, enhancing market penetration and patient access globally.-Fineline Info & Tech
